Revolution Medicines to Present Positive Phase 3 Data for Pancreatic Cancer Drug
Event summary
- Revolution Medicines will host an investor call on May 31, 2026, to discuss positive Phase 3 RASolute 302 trial results for daraxonrasib in metastatic pancreatic ductal adenocarcinoma (PDAC).
- The data was presented during the Plenary Session at the 2026 ASCO Annual Meeting.
- Daraxonrasib is a RAS(ON) multi-selective inhibitor targeting RAS-addicted cancers.
- The company's pipeline includes multiple RAS(ON) inhibitors in clinical development.
The big picture
Revolution Medicines' positive Phase 3 data for daraxonrasib marks a significant milestone in the development of targeted therapies for RAS-addicted cancers, particularly pancreatic cancer. The results could accelerate the drug's path to market and strengthen the company's position in the oncology space. The broader industry is watching closely, as successful RAS-targeted therapies have been elusive, and this could represent a breakthrough in treating a subset of aggressive cancers.
What we're watching
- Regulatory Pathway
- The pace at which Revolution Medicines advances daraxonrasib through regulatory approvals following these positive Phase 3 results.
- Market Positioning
- How these results position Revolution Medicines against competitors in the RAS-addicted cancer space.
- Pipeline Progression
- The progress of other RAS(ON) inhibitors in the company's pipeline, particularly elironrasib, zoldonrasib, and RMC-5127.
Related topics